GLP-1 Daily: Ozempic & Wegovy News
Wegovy Joins Every Medicare Drug Plan for 2027, With Prior Authorization Attached
Monday, November 16, 2026 · 7 min

Medicare's negotiated semaglutide price puts Wegovy on all 5,492 Part D plans for 2027, though not for weight loss alone. Plus European contraception advice for tirzepatide users and Novo Nordisk-funded phase 3 data on lower-dose CagriSema.
Listen
Show notes
Medicare's negotiated semaglutide price puts Wegovy on all 5,492 Part D plans for 2027, though not for weight loss alone. Plus European contraception advice for tirzepatide users and Novo Nordisk-funded phase 3 data on lower-dose CagriSema.
In this episode
- Wegovy goes from 3% to 100% of Medicare Part D plans in 2027 — Medcostclear
“For 2027, all 5,492 plans list it: 323 of 323 standalone drug plans and 5,169 of 5,169 Medicare Advantage plans with drug coverage. In both years every plan that lists Wegovy requires prior authorization.”
- CHMP backs two insulin aspart biosimilars and issues tirzepatide contraceptive advice — Diabesity Rounds Desk
“Women using an oral contraceptive are now advised to do one of two things. They can add a barrier method of contraception for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. Or they can switch to a non-oral method of contraception.”
- Lower CagriSema Doses Beat Placebo; Early Response Matters — Medscape
“Patients with overweight or obesity who received lower doses of the investigational drug CagriSema (Novo Nordisk) — 1.7 mg /1.7 mg and 1.0 mg/1.0 mg instead of the 2.4 mg/2.4 mg used in previous trials of the drug — had an estimated average weight loss of more than 20% for both…”